Array Biopharma (ARRY) Tops Q1 EPS by 10c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.06 -4.25%
EPS Growth %: -70.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -70.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.12), $0.10 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $56.9 million versus the consensus estimate of $34.5 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Arrive AI and DXC Technology partner to bring delivery tech to factories
- Lumentum shares rise on analyst upgrades, AI demand outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
